Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery

By B. Carabello. Current Cardiology Reports, 2011

6,738 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology

View Paper: https://www.semanticscholar.org/paper/7bd06a45a962f3e63a4cbced3d69ce08abb4f7cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “TAVR was compared with standard therapy in a prospective RCT of patients with severe symptomatic AS who were deemed inoperable (53,58,60).”
• Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. (2014, neutral): “Stenosis (n = 181) Regurgitation (n = 139) Combined (n = 139) P Value SelfExpandable (n = 213) BalloonExpandable (n = 246) P Value Time since last SAVR, median (IQR), ya 9 (6-12) 8 (5-11) 10(7-14) 10 (7-14) .”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “TAVR was compared with standard therapy in a prospective RCT of patients with severe symptomatic AS who were deemed inoperable (53,58,60).”
• [2017 ESC/EACTS Guidelines for the management of valvular heart disease]. (2017, methodology): “I C SAVR is recommended in pa ents at low surgical risk (STS or EuroSCORE II 4% or logis c EuroSCORE I 10% and no other risk factors not included in these scores, such as frailty, porcelain aorta, sequelae of chest radiation).93 I B TAVI is recommended in pa ents who are not suitable for SAVR as a”
• Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. (2014, methodology): “The meta-analysis estimate was then adjusted based on the lower 95% confidence boundary of 43% in the standard therapy arm of inoperable patients in PARTNER (Placement of Aortic Transcatheter Valve Trial) B (4).”